This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Tavneos (avacopan)
General Description:
Tavneos (avacopan) is a prescription oral medication used as an add-on treatment to standard therapy, including glucocorticoids, for adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
Avacopan is a complement C5a receptor inhibitor that works by blocking the inflammatory pathway driven by C5a, reducing immune-mediated damage to blood vessels. By targeting this pathway, Tavneos helps control disease activity while potentially reducing the need for high-dose glucocorticoids.
Disease Indications:
ANCA-Associated Vasculitis
Manufacturer:
ChemoCentryx
Usage:
Oral
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Pharmaceuticals and Medical Devices Agency (PMDA, Japan)
Package:
• Capsules × 30 × 10 mg
• Capsules × 180 × 10 mg
Shipping:
Room Temperature Shipping
Tavneos is stable at room temperature and does not require refrigeration. It is shipped under standard shipping conditions (15°C to 25°C), ensuring consistent quality and efficacy throughout transit.
Standard shipping is cost-effective while maintaining the integrity and therapeutic effectiveness of the medication.
How to Access Tavneos (avacopan) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Tavneos (avacopan) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
